2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, 2024 / San Diego, CA
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
M3554, a Novel Anti-GD2 Antibody Drug Conjugate
Amendt | Oral #ND08
Machine Learning—Spatial Quantification of the Tumor Microenvironment Identifies Differences Associated with Response to Bintrafusp Alfa vs. Pembrolizumab Treatment in Phase 3 INTR@PID Lung 037 Study
Abel | Poster #6179
Combined Inhibition of ART and ATM with Tuvusertib and Lartesertib (M4076) Impacts the Tumour Microenvironment
Laaber | Poster #5617
In Vitro Evaluation of Myelosuppressive Effects of the ATRi Tuvusertib and ATMi Lartesertib (M4076), Alone and in Combination
Mukker | Poster #7186
First-in-Human Trial of TIGIT Inhibitor M6223 as Monotherapy or in Combination with Bintrafusp Alfa (BA) in Patients with Advanced Solid Untraceable Tumors
Naing | Poster #CT184
A Phase 1 Study of the IAP Inhibitor Xevinapant (Debio 1143) to Evaluate Food Effect and Drug-Drug Interactions with a Proton Pump Inhibitor in Healthy Volunteers
Nicolas-Métral | Poster #CT140
Preclinical Efficacy and Safety of M9140, a Novel Antibody-Drug Conjugate (ADC) with Topoisomerase 1 (TOP1) Inhibitor Payload Targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5)-Expressing Tumors
Raab-Westphal | Poster #2362
Phase Ib Trial of ATRi Tuvusertib + ATMi Lartesertib (M4076) in Patients with Advanced Solid Tumors
Siu | Poster #CT063
M9657, a Tumor-Targeted CD137 Agonist, Induced Significant Antitumor Immunity in Combination with Anti-PD-1 Antibody
Xu | Poster #5305
Extended Treatment with IAP inhibitor Xevinapant Post Radiotherapy Improves Therapeutic Efficacy and Promotes Antitumor Immunity in Preclinical Models
Yeung | Poster #2921
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: